姜文奇;巴一;冯继锋;史艳侠;张俊;沈波;邢镨元;

• 1:中国抗癌协会肿瘤临床化疗专业委员会
• 2:中国抗癌协会肿瘤支持治疗专业委员会
• 3:中山大学肿瘤防治中心
• 4:天津医科大学肿瘤医院

摘要(Abstract)：

<正>恶心、呕吐是肿瘤药物治疗的常见不良反应。在我国,恶心、呕吐的预防和治疗以5-羟色胺(5-hydr oxytryptamine,5-HT)3受体拮抗剂联合地塞米松作为主流方案,但30%的恶心、呕吐仍未获得满意控制,恶心、呕吐依然是困扰和影响患者生活质量的重要因素。肿瘤药物治疗相关恶心、呕吐显著影响患者的生活质量,降低患者抗肿瘤治疗的依从性,从而影响疗效[1]。另外,严重的恶心、呕吐还

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81773279);; 广东省科技计划项目国际合作重点项目(2016A050502015)

作者(Authors): 姜文奇;巴一;冯继锋;史艳侠;张俊;沈波;邢镨元;

参考文献(References)：

• [1]Mc Donagh M,Peterson K,Thakurta S.Consideration of evidence on antiemetic drugs for nausea and vomiting associated with chemotherapy or radiation therapy in adults[J/OL].Rockville(MD);2010.[2019-08-30].https://www.ncbi.nlm.nih.gov/pubmed/25473695.
• [2]Laszlo J.Emesis as limiting toxicity in cancer chemot herapy[M].//Laszlo J.Antiemetics and Cancer Chemotherapy.Baltimore:Williams&Wilkins,1983:1-5.
• [3]Ingle RJ,Burish TG,Wallston KA.Conditionability of cancer chem otherapy patients[J].Oncol Nurs Forum,1984,11(4):97-102.
• [4]Mitchell EP.Gastrointestinal toxicity of chemotherapeutic agents[J].Semin Oncol,1992,19(5):566-579.
• [5]Richardson JL,Marks G,Levine A.The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy[J].J Clin Oncol,1988,6(11):1746-1752.
• [6]Navari RM,Aapro M.Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting[J].N Engl J Med,2016,374(14):1356-1367.
• [7]American Gastroenterological Association.American Gastroenterological Association medical position statement:nausea and vomiting[J].Gastroenterology,2001,120(1):261-263.
• [8]Craig JB,Powell BL.The management of nausea and vomiting in clinical oncology[J].Am J Med Sci,1987,293(1):34-44.
• [9]Borison HL,Wang SC.Physiology and pharmacology of vomiting[J].Pharmacol Rev,1953,5(2):193-230.
• [10]Seigel LJ,Longo DL.The control of chemotherapy-induced emesis[J].Ann Intern Med,1981,95(3):352-359.
• [11]Chow R,Chiu L,Navari R,et al.Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting(CINV)as reported in phase I and II studies:a systematic review[J].Support Care Cancer,2016,24(2):1001-1008.
• [12]Singh P,Yoon SS,Kuo B.Nausea:a review of pathophysiology and therapeutics[J].Therap Adv Gastroenterol,2016,9(1):98-112.
• [13]Quigley EM,Hasler WL,Parkman HP.AGA technical review on nausea and vomiting[J].Gastroenterology,2001,120(1):263-286.
• [14]Hickok JT,Roscoe JA,Morrow GR,et al.5-Hydroxy tryptamine-receptor antagonists versus prochlor perazine for control of delayed nausea caused by doxorubicin:a URCC CCOP randomised controlled trial[J].Lancet Oncol,2005,6(10):765-772.
• [15]Warr DG,Street JC,Carides AD.Evaluation of risk factors predictive of nausea and vomiting with current standard-ofcare antiemetic treatment:analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy[J].Support Care Cancer,2011,19(6):807-813.
• [16]Kris MG,Gralla RJ,Clark RA,et al.Incidence,course,and severity of delayed nausea and vomiting following the administration of high-dose cisplatin[J].J Clin Oncol,1985,3(10):1379-1384.
• [17]Moher D,Arthur AZ,Pater JL.Anticipatory nausea and/or vomiting[J].Cancer Treat Rev,1984,11(3):257-264.
• [18]Jacobsen PB,Redd WH.The development and management of chemotherapy-related anticipatory nausea and vomiting[J].Cancer Invest,1988,6(3):329-336.
• [19]Roila F,Hesketh PJ,Herrstedt J,et al.Prevention of chemotherapy-and radiotherapy-induced emesis:results of the 2004Perugia International Antiemetic Consensus Conference[J].Ann Oncol,2006,17(1):20-28.
• [20]Navari RM.Management of chemotherapy-induced nausea and vomiting:focus on newer agents and new uses for older agents[J].Drugs,2013,73(3):249-262.
• [21]National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology:Antiemesis.Version 1.2019[OL].(2019-02-28)[2019-8-30].https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
• [22]Roila F,Molassiotis A,Herrstedt J,et al.2016 MASCC and ESMO guideline update for the prevention of chemotherapyand radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients[J].Ann Oncol,2016,27(suppl 5):v119-v133.
• [23]Herrstedt J.Antiemetics:an update and the MASCC guidelines applied in clinical practice[J].Nat Clin Pract Oncol,2008,5(1):32-43.
• [24]Hesketh PJ,Grunberg SM,Herrstedt J,et al.Combined data from two phaseⅢtrials of the NK1 antagonist aprepitant plus a5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting:effect of gender on treatment response[J].Support Care Cancer,2006,14(4):354-360.
• [25]Hesketh PJ,Kris MG,Grunberg SM,et al.Proposal for classifying the acute emetogenicity of cancer chemotherapy[J].J Clin Oncol,1997,15(1):103-109.
• [26]Roila F,Herrstedt J,Aapro M,et al.Guideline update for MASCCand ESMO in the prevention of chemotherapy-and radiot herapyinduced nausea and vomiting:results of the Perugia consensus conference[J].Ann Oncol,2010,21(Suppl 5):v232-v243.
• [27]Ng TL,Hutton B,Clemons M.Chemotherapy-induced nausea and vomiting:time for more emphasis on nausea?[J].Oncologist,2015,20(6):576-583.
• [28]Zhang L,Qu X,Teng Y,et al.Efficacy of thalidomide in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy:a randomized,multicenter,double-blind,placebo-controlled phase III trial(CLOG1302 study)[J].J Clin Oncol,2017,35(31):3558-3565.
• [29]Figueroa-Moseley C,Jean-Pierre P,Roscoe JA,et al.Behavioral interventions in treating anticipatory nausea and vomiting[J].J Natl Compr Canc Netw,2007,5(1):44-50.
• [30]Ezzo J,Vickers A,Richardson MA,et al.Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting[J].J Clin Oncol,2005,23(28):7188-7198.
• [31]Razavi D,Delvaux N,Farvacques C,et al.Prevention of adjustment disorders and anticipatory nausea secondary to adju vant chemotherapy:a double-blind,placebo-controlled study assessing the usefulness of alprazolam[J].J Clin Oncol,1993,11(7):1384-1390.
• [32]Navari RM,Nagy CK,Gray SE.The use of olanzapine versus meto clopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy[J].Support Care Cancer,2013,21(6):1655-1563.
• [33]Llombart-Cussac A,Ramos M,Dalmau E,et al.Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy.Results from the Spanish Breast Cancer Group/2009-02 study[J].Eur J Cancer,2016,58:122-129.
• [34]Navari RM.5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy[J].Biochim Biophys Acta,2015,1848(10 Pt B):2738-2346.
• [35]Karthaus M,Schiel X,Ruhlmann CH,et al.Neurokinin-1receptor antagonists:review of their role for the prevention of chemo therapy-induced nausea and vomiting in adults[J].Expert Rev Clin Pharmacol,2019,12(7):661-680.
• [36]Spinelli T,Moresino C,Baumann S,et al.Effects of combined netupitant and palonosetron(NEPA),a cancer supportive care antiemetic,on the ECG of healthy subjects:an ICH E14thorough QT trial[J].Springerplus,2014,3:389.
• [37]Schwartzberg L,Barbour SY,Morrow GR,et al.Pooled analysis of phaseⅢclinical studies of palonosetron versus ondansetron,dolasetron,and granisetron in the prevention of chemotherapy-induced nausea and vomiting(CINV)[J].Support Care Cancer,2014,22(2):469-477.
• [38]Doggrell SA,Hancox JC.Cardiac safety concerns for ondansetron,an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia[J].Expert Opin Drug Saf,2013,12(3):421-431.
• [39]United States Food and Drug Administration.FDA Drug Safety Communication:New information regarding QT prolongation with ondansetron(Zofran)[OL].(2017-11-12)[2019-08-30].https://www.fda.gov/drugs/drug-safety-and-availability/fdadrug-safety-communication-new-information-regarding-qtprolongation-ondansetron-zofran.
• [40]Brygger L,Herrstedt J,Academy of Geriatric Cancer R.5-Hydroxytryptamine3 receptor antagonists and cardiac side effects[J].Expert Opin Drug Saf,2014,13(10):1407-1422.
• [41]Andrea C Tricco,Charlene Soobiah,Wing Hui,et al.Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin(5-HT3)receptor antagonists:a systematic review[J].BMC Pharmacol Toxicol,2015,16:1.
• [42]赵娅琴，王瑾，刘端祺，等．甲磺酸多拉司琼与盐酸格拉司琼预防化疗致恶心呕吐的临床对照研究[J]．华西药学杂志，2015,30(1):128-130．
• [43]Navari RM,Qin R,Ruddy KJ,et al.Olanzapine for the prevention of chemotherapy-induced nausea and vomiting[J].N Engl J Med,2016,375(2):134-142.